SIRT7 inhibitor 97491

SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC 50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway. In Vitro SIRT7 inhibitor 97491 (1-10 μM) reduces cell growth in MES-SA cells, without causing cytotoxicity in HEK293 cells. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation AssayCell Line: Human uterine sarcoma MES-SA cells Concentration: 1, 5, 10 μM Incubation Time: 72 hours Result: Led to more than 50% decrease in cell proliferation at concentrations of 5 and 10 μM. Cell Cytotoxicity AssayCell Line: Human embryonic kidney cell line HEK293 cells Concentration: 1, 5, 10 μM Incubation Time: 24 hours Result: HEK293 cells were almost unaffected. In Vivo SIRT7 inhibitor 97491 (2 mg/kg; intraperitoneally injected; for 3 weeks, except on weekends) inhibits tumor growth in xenograft mice . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Balb/c nude mice (18-20 g; 6-8 weeks old) with MES-SA cells Dosage: 2 mg/kg Administration: Intraperitoneally injected; for 3 weeks, except on weekends. Result: Inhibited cancer growth in vivo. Form:Solid IC50& Target:SIRT7 325 nM (IC 50 )

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet